10-Q: Allakos Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update

Allakos Inc. reported a net loss of $97.8 million for the first six months of 2024, alongside updates on their clinical programs and a recent restructuring.

Summary

• Allakos Inc., a clinical-stage biopharmaceutical company, reported a net loss of $97.8 million for the six months ended June 30, 2024, compared to a net loss of $77.5 million for the same period in 2023.
• The company's operating expenses totaled $101.7 million for the first half of 2024, which included a $27.3 million impairment charge on long-lived assets.
• Research and development expenses decreased to $54.2 million for the first six months of 2024, down from $60.4 million in the same period of 2023.
• General and administrative expenses also decreased to $20.1 million for the first half of 2024, compared to $22.5 million in the first half of 2023.
• As of June 30, 2024, Allakos had $123.1 million in cash, cash equivalents, and marketable securities.
• The company believes this cash balance is sufficient to fund operations for at least the next 12 months.
• Allakos is focusing on the development of AK006, which targets mast cells, and has halted development of lirentelimab (AK002).
• A reorganization plan was implemented in early 2024, reducing the workforce by approximately 50% to cut operating costs.
• The company expects data from the AK006 chronic spontaneous urticaria (CSU) cohort to be available by the end of 2024.
• Allakos also expects to report safety, pharmacokinetic (PK), and pharmacodynamic (PD) data for subcutaneous (SC) AK006 in the third quarter of 2024.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the significant net loss, impairment charge, and halting of lirentelimab development. However, the focus on AK006 and the company's belief that it has sufficient cash for the next 12 months provide some positive aspects.

Positives

• The company has sufficient cash to fund operations for at least the next 12 months.
• Phase 1 trial data for intravenous AK006 showed promising results with high receptor occupancy and a favorable safety profile.
• The company is focusing on the development of AK006, which has shown potential in preclinical studies.
• The company has developed a subcutaneous formulation of AK006.
• Operating expenses have decreased due to the reorganization plan and halting of lirentelimab development.

Negatives

• The company incurred a significant net loss of $97.8 million for the first six months of 2024.
• A $27.3 million impairment charge was recorded on long-lived assets.
• The company has an accumulated deficit of $1,216.3 million.
• The company has halted development of lirentelimab after unfavorable clinical trial results.
• The company reduced its workforce by approximately 50%.

Risks

• The company is a clinical-stage biotechnology company with a limited operating history and has incurred significant losses since inception.
• The company's future success is dependent on the successful development and commercialization of its product candidates, particularly AK006.
• The company may require additional capital to fund its operations and development programs.
• The company's stock price has recently been below the minimum listing requirements of the Nasdaq Global Select Market, which could lead to delisting.
• The company faces risks related to clinical trial outcomes, regulatory approvals, and competition from other companies.
• The company relies on third parties for manufacturing and clinical trials, which introduces risks related to quality and timelines.

Future Outlook

The company expects to report subcutaneous AK006 safety, PK, and PD data in the third quarter of 2024 and data from the AK006 CSU cohort by the end of 2024. Allakos believes its current cash balance is sufficient to fund operations for at least the next 12 months.

Management Comments

• Management believes that the current cash, cash equivalents and investments will be sufficient to fund the company's operations for at least the next 12 months.
• Management expects to incur additional operating losses in the future as the company continues to develop its product candidates.
• Management stated that the company has prioritized its AK006 development efforts based on the probability of clinical and regulatory success, unmet medical need and potential market opportunity.

Industry Context

The company is operating in the competitive biopharmaceutical industry, focusing on developing therapeutics for allergic, inflammatory, and proliferative diseases. The decision to halt lirentelimab development and focus on AK006 reflects a strategic shift based on clinical trial results and market potential. The company's focus on mast cell-driven conditions aligns with a growing understanding of the role of these cells in various diseases.

Comparison to Industry Standards

• Allakos's cash burn rate is significant, with a net loss of $97.8 million in the first six months of 2024, which is typical for clinical-stage biotech companies.
• The company's decision to halt lirentelimab development after unfavorable clinical results is a common occurrence in the industry, highlighting the high risk and uncertainty associated with drug development.
• The focus on AK006 and mast cell-driven conditions is a strategic move, as there is a growing interest in this area, with companies like Blueprint Medicines and Deciphera Pharmaceuticals also targeting mast cell disorders.
• The company's cash runway of at least 12 months is relatively standard for biotech companies, but they will likely need to raise additional capital in the future.
• The 50% workforce reduction is a significant restructuring, which is not uncommon for companies that have experienced setbacks in clinical trials or are shifting their focus.

Corporate Governance

Stakeholder Impact

• Shareholders are negatively impacted by the net loss and the decrease in the company's stock price.
• Employees were impacted by the 50% workforce reduction.
• The company's focus on AK006 may benefit patients with mast cell-driven conditions if the drug is successful.
• The company's suppliers and contract research organizations may be impacted by the changes in the company's development programs.

Next Steps

• The company will continue the Phase 1 clinical trial of AK006.
• The company expects to report subcutaneous AK006 safety, PK, and PD data in the third quarter of 2024.
• The company expects data from the AK006 CSU cohort to be available by the end of 2024.
• The company will continue to evaluate and develop other immunomodulatory targets.

Key Dates

Keywords

AK006, mast cells, clinical trial, biopharmaceutical, research and development, financial results, reorganization, lirentelimab, chronic spontaneous urticaria, subcutaneous formulation